The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.

Although patients with acquired T790M had longer median post-afatinib-progression survival (35.3 months) than patients without acquired T790M mutations (17.8 months), the difference did not reach statistical significance ( p = 0.616) (Figure 3B ).

also in 111,027 other papers